-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Multiple myeloma (MM) is an incurable disease that has a significant negative impact on patients' health-related quality of life
(HRQoL) .
Patients with relapsed/refractory MM (RRMM) often receive multiple regimens, including immunomodulatory drugs and proteasome inhibitors (PIs)
Multiple myeloma (MM) is an incurable disease that has a significant negative impact on patients' health-related quality of life
Daratumumab, an anti-cd38 monoclonal antibody with a mechanism of action that directly targets tumors and immunomodulation, is approved by the U.
In the phase 3 APOLLO (NCT03180736) trial, subcutaneous (SC) daratumumab in combination with pomalidomide dexamethasone (D-Pd) was significantly more effective in patients with relapsed/refractory multiple myeloma (RRMM).
Figure 1: Poor EORTCQLQ-C30 (A) GHS, (B) Physical Function, (C) Emotional Function, (D) Pain, (E) Fatigue Score, EORTCQLQ-MY20 (F) Disease Symptoms and (G) Treatment Score Mean change in response from baseline
Figure 2: Proportion of patients with improved*(A) and **(B) worsening PROs
Figure 2: Proportion of patients with improved*(A) and **(B) worsening PROsThe median duration of treatment was 11.
5 months for D-Pd and 6.
6 months for Pd
.
PRO adherence rates were high and similar in both groups
The median duration of treatment was 11.
5 months for D-Pd and 6.
Overall, these results suggest that patients' health-related quality of life remained stable when daratumumab was added to Pd (pomalidomide and dexamethasone), with some results in favor of D-Pd versus dexamethasone.
Original source:
Terpos, E ,Dimopoulos, MA ,Boccadoro, M , et al.
Terpos, E ,Dimopoulos, MA ,Boccadoro, M , et al.
Health-related quality of life in patients with relapsed/refractory multiple myeloma treated with pomalidomide and dexamethasone ± subcutaneous daratumumab: Patient-reported outcomes from the APOLLO trial .
Am J Hematol .
2022 ; 1-10 .
doi: 10.
1002 /ajh.
26480 Leave a comment here
